Novo Nordisk A/S (Novo Nordisk A/S) NonCurrent Deferred Liabilities : $1,487 Mil (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Novo Nordisk A/S NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Novo Nordisk A/S's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $1,487 Mil.

Novo Nordisk A/S NonCurrent Deferred Liabilities Historical Data

The historical data trend for Novo Nordisk A/S's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S NonCurrent Deferred Liabilities Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

NonCurrent Deferred Liabilities

Get a 7-Day Free Trial

11.90

409.13

800.94

1,005.43

1,486.80

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
NonCurrent Deferred Liabilities	Get a 7-Day Free Trial															1,005.43	1,132.74	1,109.88	1,128.41	1,486.80

Novo Nordisk A/S NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (OTCPK:NONOF) » Definitions » NonCurrent Deferred Liabilities

Comparable Companies

Traded in Other Exchanges

NVO:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.